



SECTOR STRATEGY: BIOTECH

(BIOTECHNOLOGIES)

UKRAINIAN GLOBAL INNOVATION STRATEGY UNTIL 2030



	STRATEGY SUMMARY: BIOTECHNOLOGIES (BIOTECH)	4
	SECTION 1. SECTOR STRATEGY: BIOTECH	8
1.1	Global BioTech sector overview	9
1.2	BioTech sector development in Ukraine	18
1.3	BioTech Strengths and weaknesses in Ukraine	24
1.4	Barriers and opportunities to boost BioTech development in Ukraine	27
	SECTION 2. KEY PROJECTS: BIOTECH	31
2.1	Technology development priorities: BioTech	33
2.2	Top projects: BioTech	37



ABBREVIATIONS AND DEFINITIONS

KEY DEFINITIONS

STRATEGY Ukrainian Global Innovation Strategy until 2030

BIOTECH Biotechnologies

ABBREVIATIONS

Agr	Agriculture	mAb	Monoclonal antibody
Al	Artificial intelligence	PCR	Polymerase chain reaction
DNA	Deoxyribonucleic acid	R&D	Research and development
EU	European Union	SME	Small and medium enterprises
GMP	Good manufacturing practice	SME	Small and medium enterprises
GDP	Gross domestic product	SW	Software
HEI	Higher educational institution	USA	United States of America
IP	Intellectual property	VR	Virtual Reality
		WHO	World Health Organization





UKRAINE CAN BECOME A LEADER IN THE GLOBAL BIOTECH INDUSTRY BY DEVELOPING INNOVATIVE SOLUTIONS AND EXPORTING BIOPHARMACEUTICAL PRODUCTS

The Ukrainian Global Innovation Strategy until 2030 defines the development of the biotechnology as one of the strategic goals, the achievement of which will strengthen the innovation ecosystem and realize Ukraine's innovation potential.

UKRAINE'S FUTURE ROLE IN THE GLOBAL BIOTECH INDUSTRY

EXPORTS OF UKRAINIAN BIOPHARMACEUTICAL PRODUCTS

The strong potential of the biopharmaceutical industry allows Ukraine to become an important player in the manufacturing of innovative medicines. Enhancing government support and the increased demand for biotech solutions, e.g. regenerative medicine and mental health solutions will contribute to Ukraine's potential and its access to international markets



CREATING BIOTECHNOLOGY CLUSTERS

The formation of specialised biotechnology clusters will support the development of innovative solutions and will strengthen competitiveness. Such R&D centers will bring together Ukrainian and international biotech startups, businesses, research institutions and universities, which will allow them to share experiences, attract investments and commercialize scientific developments



INCREASING BIOFUEL PRODUCTION

The use of biotechnologies, such as fermentation, biosynthesis and pyrolysis, has a favourable impact on increasing biofuel production. Ukraine has the potential to become a leading supplier of bioethanol and biodiesel to EU countries that are switching to renewable energy



DEVELOPING BIOINFORMATICS

Expanding biobanks of genetic material and plant crops and enhancing the development and use of SW for biological research, namely the analysis of RNA, DNA, and protein structures will become an important development area for Ukraine's biotechnology. The development of tools for big data visualisation and modelling of biological processes will accelerate the implementation in the fields of medicine, pharmaceuticals and agrobiotechnology



UKRAINE HAS STRONG SCIENTIFIC POTENTIAL IN BIOTECHNOLOGY, BUT NEEDS TO STRENGTHEN STATE SUPPORT AND HARMONIZE LEGISLATION

★ STRENGTHS

- Free access to natural resources and biodiversity in Ukraine contributes to effective R&D activities
- Developed pharmaceutical industry in Ukraine, which serves as the basis for further implementation of new innovative solutions in the biopharmaceutical area.
- Availability of highly qualified specialists, developed research infrastructure and higher education institutions that prepare personnel for the sector

✓ OPPORTUNITIES

- Ukraine's integration into the EU and harmonization of legislation will facilitate the export of Ukrainian biotechnology products to international markets. Improving legislation on technology transfer and cofinancing with Ukrainian and foreign institutions
- Strong IT in Ukraine may contribute to the development of algorithms and software for biological data analysis
- Establishing public-private partnerships in BioTech for financing innovation projects and boosting startups development

× WEAKNESSES

- Insufficient financial, scientific and technical support from the state, as well as the lack of close interaction between all stakeholders in the technological ecosystem
- Instability of government policy and frequent changes in the legislative regulation of the sector in Ukraine. Imperfect IP rights protection
- Insufficient experience in the development and commercialization of biological technologies slows down the launch of innovative products

× THREATS

- Weak patenting system and innovations commercialization in Ukraine
- The war in Ukraine creates a high risk of doing business and may lead to increased political and economic instability
- The outflow of human capital, in particular scientists and researchers, may hinder the active development of BioTech



IMPLEMENTATION OF THE BIOTECH DEVELOPMENT STRATEGY IN UKRAINE REQUIRES HARMONIZATION OF LEGISLATION, FINANCING AND INFRASTRUCTURE SUPPORT

IMPLEMENTING THE STRATEGY OF THE BIOTECH SECTOR INVOLVES A NUMBER OF TASKS:

REGULATORY

Harmonizing legislation with EU norms to ensure compliance of Ukrainian BioTech products with international standards

Reducing the time for registration of BioTech products and introducing transparent procedures for clinical trials

Developing a regulatory framework for PPPs in the BioTech sector

ECONOMIC

R&D financing through government programs aimed at developing biopharmaceutical production

Introducing state guarantee mechanisms for attracting foreign investment in Ukraine's BioTech sector

Development of investment and grant programmes for biotechnology companies and start-ups

INFRASTRUCTURAL

Modernizing laboratory equipment in research institutions engaged in BioTech research

Establishment of centers and rules for collective use of equipment for business and the scientific community, after the infrastructure




1.1


*GLOBAL BIOTECH SECTOR OVERVIEW



THE GLOBAL BIOTECHNOLOGY MARKET IS REPORTING STEADY GROWTH DUE TO PUBLIC FOCUS ON ESG ASPECTS AND THE IMPACT OF THE PANDEMIC

The global biotechnology market responds to changes in the world and society. In 2018, the biotechnology market was projected to reach a size of only \$0.6 trillion by 2025, growing at a 9,5% CAGR during 2019-2025. However, the COVID-19 pandemic and growing attention to ESG aspects became powerful catalysts for the industry, triggering its accelerated growth. These factors have stimulated investment in BioTech, increased demand for innovative solutions in medicine, AgriTech, and environmental projects, thus creating conditions for doubling the market by 2030.









IN 2023, HEALTHCARE SECTOR AND BIOTECHNOLOGIES, WHICH WERE ACTIVELY APPLIED IN THIS AREA, CONTINUED DOMINATION ON THE GLOBAL BIOTECH MARKET

SEGMENTATION OF THE GLOBAL INNOVATIVE TECHNOLOGY MARKET¹





- Biotechnology innovations such as biosensors, VR applications, bioprinting, gene editing, etc. are expected to transform the global biotechnology market
- The versatility of tissue engineering and regeneration technologies, including their widespread use in the healthcare industry, will help maintain the market's dominant status during 2020-2023

- Despite the continuing dominance of the healthcare sector, the industrial processing sector has shown the fastest CAGR of 11.7% during 2021-2023. This growth is driven by the need to develop more eco-friendly solutions in the context of the sustainable development trend
- In addition to these sectors, biotechnology has applications in the defence industry, in particular, for biodefence, criminology and other strategic sectors



BIOTECHNOLOGY ALLOWS TO IMPROVE HEALTHCARE TREATMENTS AND INCREASE AGRICULTURAL PRODUCTIVITY

BIOTECH SEGMENTS BY APPLICATION AREA

		ΙТ	- [ΛГ	וכ	
п	CA	ᆫᅵ		4 i	K	

Using biotechnology to improve the diagnosis, treatment and prevention of diseases

BIOPRODUCTS	antibodies,	grov	vth	hormones,	vaccines,

enzymes, blood plasma

SENE THERAPY correction of genetic defects using

CRISPR, ZFN, TALEN and other methods

STATES CELL THERAPY using stem cells for tissue

regeneration

BIOMATERIALS bioprinting of organs for transplantation,

production of tissues for wound treatment and orthopedic surgeries

CLINICAL TRIAL organ-on-a-chip models, genetically

modified organisms, computer

modeling for clinical trials

▲ PERSONALIZED MEDICINE

selection of treatment based on the

patient's genetic profile

AGRICULTURE

Using biotechnology to improve plant yields and quality, as well as to adapt to climatic and environmental changes

MODIFIED CROPS

developing new crops enriched with nutrients (proteins, vitamins, etc.) and resistant to pests

and diseases

BIOFERTILIZERS

using microorganisms that improve the

absorption of nutrients by plants

BIOPESTICIDES

biological pest control agents



APPLICATION OF BIOTECHNOLOGY ALLOWS TO PERSONALIZE BIOLOGICAL INFORMATION AND CREATE ENVIRONMENTAL SOLUTIONS IN INDUSTRY

BIOTECH SEGMENTS BY APPLICATION AREA

BIOINFORMATICS

Individualized approach to the analysis and interpretation of genetic and biological data, as well as research of new biotechnological solutions

INDUSTRIAL PROCESSING

Creating eco-friendly and sustainable solutions through the use of biological materials and biotechnology

ANALYSIS AND RESEARCH	genome sequencing, identification of genes, their functions and mutations, analysis of proteins and their functions	BIOFUEL	production of biogas, bioethanol and biodiesel from agricultural crops
DATABASES	collection and storage of genetic information, as well as development of SW for biodata analysis	BIOPOLYMERS	developing biodegradable plastics from crops and bacteria
VR FOR DRUG DESIGN AND MOLECULAR VISUALIZATION	modeling potential new molecules, prediction of drug-protein interactions	BIOREMEDIATION	using bacteria, fungi and plants to clean up contaminated environments (i.e. soil, water, air).
PERSONALIZED MEDICINE	genetic tests for medical purposes, development of personalized medicines, food intolerance tests, gene therapy	/ INDUSTRIAL FERMENTATION	developing active substances from biological materials for detergents, paper production, etc.



KEY BIOTECH TRENDS THAT CREATE INNOVATIVE SOLUTIONS FOR MEDICINE, GENETICS AND THE DEVELOPMENT OF LIVING SYSTEMS

KEY TRENDS IN THE GLOBAL BIOTECH MARKET

ARTIFICIAL INTELLIGENCE

Using artificial intelligence in biotechnology helps to analyze large amounts of data, automate research and develop new methods of treatment and diagnosis

A technology that allows changing the genetic structure of organisms, which can be useful for the treatment of genetic diseases and the creation of accurate diagnostic methods

X STEM CELLS

Using stem cells that can differentiate into any type of body tissue opens up new opportunities for tissue and organ regeneration, as well as for research into the treatment of various diseases

TISSUE ENGINEERING AND BIOPRINTING

Technologies that represent advanced methods of creating artificial tissues and organs by using advanced technologies to "print" living cells and biological materials into predefined shapes and structures

CLINICAL PRE-TRIAL/TRIAL

The trend is focused on improving drug manufacturing processes, in particular through the use of biotechnology methods that allow creating more effective and safer medicines


SYNTHETIC BIOLOGY (SynBio)


A BioTech branch that involves the creation and editing of living systems to create new or improve existing biological systems



THE GLOBAL BIOTECH MARKET IS HOME TO A SIGNIFICANT NUMBER OF PLAYERS DEVELOPING INDUSTRIES AND OFFERING INNOVATIVE SOLUTIONS IN MEDICINE AND SCIENCE

KEY PLAYERS ON THE GLOBAL BIOTECH MARKET









THE GLOBAL BIOTECH MARKET IS HOME TO A SIGNIFICANT NUMBER OF PLAYERS DEVELOPING INDUSTRIES AND OFFERING INNOVATIVE SOLUTIONS IN MEDICINE AND SCIENCE

KEY PLAYERS ON THE GLOBAL BIOTECH MARKET







COUNTRIES AROUND THE GLOBE ARE IMPLEMENTING STRATEGIES TO DEVELOP BIOTECHNOLOGY THROUGH TAX INCENTIVES, RESEARCH SUPPORT AND INVESTMENT.

SOME EXAMPLES OF THE IMPLEMENTATION OF BIOTECHNOLOGY IN THE WORLD

GREAT BRITAIN

- In 2021, a strategy for Life Sciences Vision was adopted to develop the BioTech sector
- The government invests heavily in R&D, with such expenditures amounting to 2.9% of GDP in 2021. From 2011 to 2021, R&D expenditures as a share of GDP grew by 0.65 percentage points
- The government uses fiscal measures to stimulate the development of biotechnology. For instance, SME engaged in research and development can enjoy tax incentives of up to 230% of R&D expenditures

GERMANY

- In 1996, the government initiated the BioRegio program, which was aimed at developing BioTech clusters. As of 2022, there were 24 BioTech clusters in Germany
- As of March 2024, a strategy for the development of the biotechnology industry, the Agenda von der Biologie zur Innovation "BIO-IT", as well as a number of initiatives aimed at strengthening the country's innovation potential in BioTech are in the process of development
- Businesses engaged in biotechnology research and development may receive tax incentives in the amount of 25% of R&D expenses

INDIA

- To develop the BioTech sector, the BIRAC agency was established in 2012, and in 2021 the National Biotechnology Development Strategy was developed by the Department of Biotechnology.
- The country is attractive for US and European companies to set up production facilities due to low R&D costs, skilled labor, and diversity of biological resources
- Tax incentives for research and development range from 100% to 200% of R&D expenses

2

*BIOTECH SECTOR
DEVELOPMENT IN UKRAINE



THE DEVELOPMENT OF BIOTECH IN UKRAINE LAGS FAR BEHIND THE LEVEL OF THE LEADING COUNTRIES, BUT SHOWS POTENTIAL IN A RANGE OF TECHNOLOGIES


The need to develop biotechnology in Ukraine is driven by a number of challenges of a full-scale war, which create the need for bioengineering technologies, as well as environmental challenges such as climate change, soil degradation, water pollution, energy crisis, etc. However, according to the BioTech Innovation Index¹, Ukraine is ranked 53rd out of 54 countries surveyed with 12,5 points out of 100.

In 2022, only 16,2% of Ukraine's publications in the life sciences were related to biotechnology. Furthermore, the total number of clinical trials in Ukraine has been gradually decreasing, which indicates a low focus on the development of innovations, including those related to biotechnology in the healthcare sector. In contrast, the bioenergy industry in Ukraine has intensified, although it remains at a lower development level compared to European countries.


HEALTHCARE



INDUSTRIAL PROCESSING



AGRICULTURE





THE SIGNIFICANT ECONOMIC AND SOCIAL ROLE OF BIOTECH IN UKRAINE REQUIRES INCREASED ATTENTION TO THE MOST IMPORTANT AND PROMISING BIOTECHNOLOGIES

Among the analysed biotechnology technologies in Ukraine, the most promising for further development are the following areas:

TISSUE ENGINEERING AND REGENERATION

Significantly impacts the healthcare sector as it is used in the development of innovative treatments and contributes to the agricultural industry for the development of new crops

CELL RESEARCH

A technology opens up new opportunities for personalised medicine by creating individual models of patients' diseases. In addition, it contributes to the development of biopharmaceuticals by enabling the efficient production of drugs and their testing in cellular models

FERMENTATION


The technologies are widely used in agriculture, bioprocessing, biofuel production, and other industrial sectors in Ukraine

DEVELOPEMNT OF KEY BIOTECHNOLOGIES IN UKRAINE DEVELOPMENT - TRENDS **TISSUE** ENGINEERING AND SEQUENCING BIOPRINTING CELL RESEARCH NANOBIOTECHNOLOGY **FERMENTATION** PCR **TECHNOLOGY** INVOLVEMENT OF NEW CHROMATOGRAPHY BIO-**INFORMATICS SPECTROSCOPY** LOW HIGH **AVERAGE** CURRENT ECONOMIC CONTRIBUTION OPERATIONAL DEVELOPMENT PRIORITY DEVELOPMENT AREAS LEVEL



BIOTECHNOLOGY IS THE FOCUS OF RESEARCH BY A NUMBER OF COMPANIES AND STATE INSTITUTIONS IN UKRAINE IN THE HEALTHCARE AND AGRICULTURAL SECTORS.

CERTAIN PLAYERS ON THE UKRAINIAN BIOTECH MARKET




¹Institute of Food Biotechnology and Genomics, as well as Institute of Plant Physiology and Genetics ²The types of technology for individual companies are categorized according to open source data



THE USE OF BIOTECHNOLOGY IN INDUSTRY IS AT AN EARLIER DEVELOPMENT STAGE COMPARED TO OTHER SECTORS

CERTAIN PLAYERS ON THE UKRAINIAN BIOTECH MARKET



1.3

*BIOTECH STRENGTHS AND WEAKNESSES IN UKRAINE



UKRAINE HAS A HIGH SCIENTIFIC POTENTIAL IN THE FIELD OF BIOTECHNOLOGY, WHICH CREATES A STRONG BASIS FOR ENHANCING THE DEVELOPMENT OF THE SECTOR

UKRAINE'S STRENGTHS FOR THE DEVELOPMENT OF THE TECHNOLOGY SECTOR

- Developed scientific potential in BioTech, supported by a number of specialized institutions and private educational initiatives, e.g. "BioSchool" from BioPharma and BioTech courses from Enzym Group
- Free access to natural resources and biodiversity in Ukraine contributes to the efficient use of available resources for scientific research and development of biotechnology products
- Highly developed pharmaceutical industry serves as a basis for innovation, as it creates a solid knowledge base for further development and implementation of innovative solutions in the biopharmaceutical sector

- Large agricultural potential and experience in the use of fermentation technologies create conditions for the active development of bioenergy production and biotechnology in agriculture
- Lower cost of research in the biotechnology industry compared to the EU and North America, which can create a competitive advantage in terms of cost of innovation on international markets
- The developed IT industry, as well as a network of incubators and accelerators for IT and BioTech startups, such as the Ukrainian Startup Fund, Yep!, CfE accelerator and others, expand the opportunities for the development of bioinformatics in Ukraine



DESPITE THE EXISTING SCIENTIFIC POTENTIAL IN THE BIOTECH, THE LACK OF FINANCIAL AND REGULATORY SUPPORT HINDERS THE DEVELOPMENT OF THE SECTOR

UKRAINE'S WEAKNESSES FOR THE DEVELOPMENT OF THE TECHNOLOGY SECTOR

Lack of financial, scientific and technical support from the state, resulting in limited number of research projects in the field of biotechnology implemented by scientific institutes and HEIs

Limited domestic market due to low solvency of the population and conservatism of key industries that are end users of biotechnology

Lack of in-depth experience in commercializing BioTech solutions and weak IP protection, which hinders the launch of innovative products on the market and their active use in economic sectors

Complex and lengthy registration and licensing procedures for innovative biotechnology products, especially in the pharmaceutical sector, restraining the innovations in the market

An outdated legislative framework for major research trends, such as genome editing, clinical trials, etc., that is not in line with the rapid pace of scientific development and international standards

Unstable government policies and unpredictable changes in legislation that complicate the process of planning research and implementation of new biotechnology

1.4

*BARRIERS & OPPORTUNITIES TO BOOST BIOTECH DEVELOPMENT IN UKRAINE



INSUFFICIENT DEVELOPMENT OF INFRASTRUCTURE AND REGULATORY CAPABILITIES IN UKRAINE HINDERS INTERNATIONAL COOPERATION AND LIMITS THE INVOLVEMENT OF SCIENTISTS IN THE FIELD OF BIOTECHNOLOGY

BARRIERS TO THE DEVELOPMENT OF THE TECHNOLOGY SECTOR IN UKRAINE

OUTFLOW OF SCIENTIFIC PERSONNEL


A significant number of scientists and researchers find more favorable conditions for conducting research in the field of BioTech abroad

LACK OF COOPERATION AMONG ECOSYSTEM PLAYERS

Lack of cooperation between science, business and the state hinders the commercialization of research and the introduction of new biotechnologies

WEAK PROTECTION OF THE IP

The low level of IP rights protection in Ukraine does not provide a secure environment for biotechnology developers, negatively affecting their interest in developing the industry



LACK OF MODERN EQUIPMENT

Outdated scientific and laboratory equipment and necessity of its audit reduces the innovativeness of biotechnology developments, that affects Ukraine's competitiveness in international markets


LIMITED ACCESS TO SCIENTIFIC INFRASTRUCTURE

The lack of innovation infrastructure open to business (science parks, innovation zones, etc.) reduces opportunities for research and implementation of developments in the real sector of the economy



IMPROVING THE REGULATORY FRAMEWORK AND ACTIVE COOPERATION IN THE BIOTECH SECTOR WILL PROMOTE R&D AND COMPETITIVENESS OF INNOVATIONS

KEY OPPORTUNITIES TO PROMOTE THE DEVELOPMENT OF THE SECTOR






FINANCIAL INCENTIVES AND INFRASTRUCTURE DEVELOPMENT WILL CREATE OPPORTUNITIES FOR BIOTECH PLAYERS TO DEVELOP THEIR INNOVATIVE IDEAS IN UKRAINE

KEY OPPORTUNITIES TO PROMOTE THE DEVELOPMENT OF THE SECTOR



FAVORABLE REGULATORY ENVIRONMENT

Establishment of centers for collective use of equipment for the scientific community and business in the field of BioTech and Life Sciences



PARTNERSHIP DEVELOPMENT

> Conservation and modernization of laboratory equipment in higher education institutions and research institutions conducting research in the field of BioTech

Introduce a single electronic platform for procurement coordination and transparent placement of public orders. Ensuring the implementation of government orders for BioTech solutions

FINANCIAL **INCENTIVES** **INFRASTRUCTURE** DEVELOPMENT

Facilitating the launch of pilot production to scale up new biotechnology developments in Ukraine

03

04



THE BIOTECH INDUSTRY STRATEGY ENVISAGES 6 PRIORITY AREAS AND IDENTIFIES 3 TOP PROJECTS FOR PRIORITY IMPLEMENTATION IN UKRAINE

PRIORITY AREAS

- R&D hub for biotechnology
- Biobank of materials
- Bioprinting

- DNA Sequencing and bioinformatics
- Biotechnology for agriculture
- Fermented products and biosynthesis

TOP PROJECTS

BIO-PHARMACEUTICAL MANUFACTURING

TISSUE ENGINEERING TECHNOLOGIES

BIOCLUSTER

2.1

*TECHNOLOGY DEVELOPMENT PRIORITIES: BIOTECH



DEVELOPMENT OF INNOVATION INFRASTRUCTURE IN UKRAINE WILL ACCELERATE AND MODERNIZE RESEARCH IN THE BIOTECHNOLOGY AREA

TECHNOLOGY DEVELOPMENT PRIORITIES

R&D HUB FOR BIOTECHNOLOGY

BUILDING A RANGE OF R&D SPACES FOR DIFFERENT BIOTECH AREAS TO PROVIDE RESEARCH IN COOPERATION WITH LEADING UNIVERSITIES, RESEARCH INSTITUTIONS AND BUSINESSES

ADVANTAGES

- Providing access to advanced equipment for leading scientists, startups and companies
- Quick prototyping and testing of new technologies, which reduces the time to find innovations
- Enhancement of innovative developments through the implementation of joint business and science projects

KEY MEASURES

- Establishing cooperation with key stakeholders of the future R&D hub
- Audit of the existing infrastructure base that will become the basis for the hub and modernization of laboratory equipment
- Introducing financial support mechanisms, including partial reimbursement of expenses for joint R&D projects

O2 BIOBANK OF MATERIALS

SPECIALIZED STORAGE FOR PRESERVING BIOLOGICAL SAMPLES (TISSUES, CELLS, DNA, ORGANS, FLUIDS, ETC.) FOR FURTHER RESEARCH

ADVANTAGES

- Improving the accuracy of disease diagnosis by analyzing samples in biobanks
- Promoting scientific discoveries through the ability to conduct research in biopharmaceuticals and genetics based on biological materials
- Possibility of long-term storage of biological samples

KEY MEASURES

- Developing clear regulatory standards to ensure the confidentiality of biobank and material donor data
- Implementing unified rules for the storage and transportation of biological samples in accordance with international standards
- Attracting investment for the development of biobanks and bioinformatic solutions

THE DEVELOPMENT OF BIOPRINTING AND GENOME SEQUENCING TECHNOLOGIES WILL CONTRIBUTE TO THE PERSONALIZATION OF MEDICINE

TECHNOLOGY DEVELOPMENT PRIORITIES

03 BIOPRINTING

CREATION OF TISSUES AND ORGANS THROUGH 3D PRINTING BASED ON BIOLOGICAL MATERIALS SUCH AS CELLS, BIOPOLYMERS, AND OTHERS

ADVANTAGES

- The ability to quickly create prototypes of tissues and organs for use in regenerative medicine
- Creating the ability to conduct clinical pre-trials on artificial organs, reducing the need for animal testing
- Optimizing the cost of producing complex structures and reducing resource use

KEY MEASURES

- Investing in research on new biopolymers and cellular structures for bioprinting
- Partnering with medical institutions to test and implement technologies
- Developing training and re-skilling programs for specialists in the area of bioprinting

O4 DNA SEQUENCING AND BIOINFORMATICS

TECHNOLOGY BASED ON GENOMIC ANALYSIS TO CREATE INDIVIDUALIZED TREATMENT AND PREVENTION PLANS

ADVANTAGES

- Reducing side effects and increasing the effectiveness of therapy due to precise drug selection
- Possibility to predict the risk of developing diseases and increase life expectancy in Ukraine
- Early diagnosis of rare and complex diseases that cannot be diagnosed by traditional methods

KEY MEASURES

- Opening a genetic laboratory specializing in DNA sequencing
- Integrating genetic information into medical records and electronic systems
- Organizing information campaigns to popularize the benefits of genome analysis



WIDESPREAD USE OF BIOTECHNOLOGY IN THE AGRICULTURAL SECTOR AND INDUSTRIAL PROCESSING WILL CONTRIBUTE TO THE INNOVATIVE GROWTH OF INDUSTRIES

TECHNOLOGY DEVELOPMENT PRIORITIES

05 BIOTECHNOLOGY FOR AGRICULTURE

BIOTECHNOLOGIES AIMED AT INCREASING YIELDS, PROTECTING PLANTS AND REDUCING NEGATIVE ENVIRONMENTAL IMPACT

ADVANTAGES

- Developing climate-resistant plant varieties helps ensure stable yields even in adverse conditions
- Reducing the use of chemicals that have a negative impact on soil and water resources
- Opportunity to improve product quality by increasing the content of nutrients in agricultural crops

KEY MEASURES

- Modernizing regulatory standards for the use of biotechnology in agriculture
- Providing grant programs to agro-industrial companies engaged in R&D in BioTech
- Introducing tax incentives for farmers switching to biotechnology

()6 FERMENTED PRODUCTS AND BIOSYNTHESIS

APPLICATION OF FERMENTATION TECHNOLOGIES TO ENHANCE THE PRODUCTION OF BIODEGRADABLE POLYMERS, BIOENERGY, ANTIBIOTICS AND OTHER FERMENTED PRODUCTS

ADVANTAGES

- Environmental benefits fermentation and biosynthesis is more environmentally friendly processes than chemical synthesis
- Reduced costs –fermentation and biosynthesis processes have lower costs than traditional chemical methods, making them more cost-effective
- High efficiency microorganisms can quickly process large volumes of raw materials, which increases production efficiency


KEY MEASURES

- Opening a genetic laboratory specializing in DNA sequencing, storage and analysis of genetic information
- Integration of genetic information into medical records and electronic systems
- Organization of information campaigns to popularize the benefits of genome analysis

2.2 *TOP PROJECTS: BIOTECH




DEVELOPMENT OF THE BIOPHARMACEUTICAL SEGMENT IN THE WORLD



The biopharmaceutical industry develops medicines that are produced by living cells or organisms and created through biological processes. The industry includes a wide range of biological products, such as vaccines, gene therapy, biotissues, blood components, and others,. One of the most common biological products are monoclonal bodies, which are used to threat chronic diseases. Their advantage is high precision, as they affect only targeted cells without harming healthy ones

GOVERNMENT INCENTIVES FOR BIOPHARMACEUTICAL DEVELOPMENT



State funding for the development of biotechnology vaccines and the creation of BioTech centers

Public funding through grants and loans, as well as public-private

partnerships

EXAMPLES OF BIOPHARMACEUTICAL COMPANIES



The largest segment in 2024 Monoclonal antibodies

SANOFI

developments in the field of immunotherapy

III FRANCE

ROCHE

focus on monoclonal bodies and immunotherapy

SWITZERLAND

BIOGEN, INC.

biological products in the field of neurology.



BAYER

recombinant proteins, antibodies and vaccines



GERMANY



GROWTH DRIVERS OF BIOPHARMACEUTICAL PRODUCTION IN THE WORLD



DEVELOPMENT OF BIOENGINEERING TECHNOLOGIES

Technologies, such as CRISPR-Cas9¹, are transforming approaches to the treatment of genetic diseases and creating new markets for biopharmaceutical products



CONSEQUENCES OF THE COVID-19 EPIDEMIC

The emergence of new infectious diseases, such as COVID-19, has necessitated the rapid development of vaccines and antiviral drugs, and has stimulated public and private investment in modernizing biopharmaceutical infrastructure and expanding production capacity



RISING DEMAND FOR MONOCLONAL ANTIBODY (MAB) TREATMENT



MAb's are used to treat cancer, autoimmune diseases and viral infections. The production of mAbs requires high-tech equipment and bioreactors, specialized laboratories for large-scale production of antibodies, and optimization of biotechnological processes to reduce production costs

FIGHTING ANTIMICROBIAL RESISTANCE (AMR)




WHO programmes and private sector initiatives are aimed at funding research into new antibiotics and antimicrobials, developing alternative therapies, including phagotherapy and immunomodulators, and introducing government support mechanisms for pharmaceutical companies working to combat AMR



DRIVERS AND CONSTRAINTS TO DEVELOPMENT IN UKRAINE

DRIVERS OF DEVELOPMENT IN UKRAINE





The pharmaceutical sector is recognized as strategically important for the provision of medicines to the population in times of war

CONSTRAINTS TO DEVELOPMENT IN UKRAINE

✓ UNDERDEVELOPED MEDICAL INFRASTRUCTURE

Insufficient number of modern laboratories and GMP-compliant manufacturing facilities reduces the ability to produce high-quality biological products

The outflow of talented professionals abroad due to low wages, limited career opportunities and insufficient funding for research

HIGH COST OF DEVELOPMENT

The development and patenting of new biological products requires a long-term injection of significant financial resources, which is a challenge for the Ukrainian market

LOW LEVEL OF TRUST IN BIOLOGICAL PRODUCTS

Lack of awareness of the public and healthcare professionals about the benefits of biotechnology causes distrust in their use



ASSESSMENT OF THE FEASIBILITY OF IMPLEMENTING THE TOP PROJECT IN UKRAINE

X REQUIRED MEASURES

IMPROVING THE LEGAL AND REGULATORY FRAMEWORK

- Improving the legislation regulating pharmaceutical activity and the patenting
- Harmonization of Ukrainian legislation with EU standards

DEVELOPING SECTORAL COOPERATION

- Developing cooperation between pharmaceutical manufacturers and research institutions for joint R&D
- Establishing cooperation with universities in the training of BioTech specialists


STRENGTHENING GOVERNMENT SUPPORT

- Providing state loan programs for the development of biopharmaceutical production
- Launching grant programs to finance R&D in BioTech

EXPECTED DURATION OF THE TOP PROJECT

Medium-term

3-5 YEARS




EXPECTED EFFECT

- ✓ Increasing the level of scientific research to create new, more effective and innovative medicines
- ✓ Providing the domestic market with biopharmaceuticals to reduce dependence on imports
- ✓ Increasing the volume of domestic biopharmaceutical production and expanding Ukraine's presence in the global pharmaceutical market, strengthening the country's innovation potential through the development of advanced biotechnologies and international integration of the Ukrainian BioTech sector

X

TOP PROJECT 2 - TISSUE ENGINEERING TECHNOLOGIES

DEVELOPMENT OF THE TISSUE ENGINEERING SEGMENT IN THE WORLD



Tissue engineering is the technology for creation and modification of biological tissues by using stem cells, growth factors, differentiated cells, etc. The technology has the widest application in the healthcare sector, namely in orthopedics and dentistry for bone and cartilage regeneration, as well as in reconstructive medicine for restoration of damaged skin. In addition, it is being actively used in the agricultural industry in the areas of meat cultivation, genetic modification and plant propagation

THE LATEST INNOVATIVE DEVELOPMENTS



"Smart" biomaterials are tissues that can respond to external stimuli such as temperature, pH, and electric fields, imitating the natural behavior of tissues



Organ-on-a-chip – creation of miniature tissue models on chips that imitate the natural behavior of tissues for research in controlled laboratory conditions

COMPANIES OPERATING IN THE FIELD OF TISSUE ENGINEERING

The largest region in 2023

38%

North America

The largest segment in 2023

31%

Orthopedic product



REGENERATIVE MEDICINE GROUP

creation of human organs for transplantation



MOSA MEAT

cultured beef based on tissue engineering



PLANTFORM CORPORATION

Changes in the genetic characteristics of agricultural plants



TOP PROJECT 2 - TISSUE ENGINEERING TECHNOLOGIES

GROWTH DRIVERS OF TISSUE MEDICINE TECHNOLOGIES IN THE WORLD



TECHNOLOGICAL INNOVATIONS

The introduction of the latest technologies, such as 3D printing and bioengineering, is helping to create more effective solutions in regenerative medicine



LACK OF DONOR MATERIAL FOR TRANSPLANTATION

According to the WHO, only 10% of the global need for organ transplants is met worldwide, creating an urgent need to develop alternative methods, such as bioprinting

INCREASE IN THE NUMBER OF CHRONIC DISEASES AND INJURIES



The increase in the number of patients with chronic diseases and injuries raises the need for effective treatment methods, including stem cells and biomaterials

GLOBAL GROWTH DRIVERS

DEMOGRAPHIC CHANGES



The increase in life expectancy and, as a result, the aging of the population, increases the need for methods of tissue and organ restoration




TOP PROJECT 2 - TISSUE ENGINEERING TECHNOLOGIES

DRIVERS AND CONSTRAINTS TO DEVELOPMENT IN UKRAINE

DRIVERS OF DEVELOPMENT IN UKRAINE





The developed IT industry allows to create technological solutions that integrate with tissue medicine

DEVELOPMENT CONSTRAINTS IN UKRAINE

DIFFICULTY IN ACCESSING THE LATEST TECHNOLOGIES

The high cost of equipment and materials required for tissue engineering makes it difficult to integrate innovative solutions in Ukraine



Complex and lengthy approval procedures for new medical technologies can slow down their implementation

Insufficient number of specialized laboratories and centers slows down the development of the industry

LOW LEVEL OF COOPERATION BETWEEN SCIENCE AND BUSINESS

Limited opportunities for integrating scientific discoveries into business processes and medical institutions, including military hospitals, hinder the development of the industry



TOP PROJECT 2 - TISSUE ENGINEERING TECHNOLOGIES

ASSESSMENT OF THE FEASIBILITY OF IMPLEMENTING THE TOP PROJECT IN UKRAINE



ENHANCING THE REGULATORY ENVIRONMENT

- Introducing accelerated approval procedures for innovative biotechnologies
- Harmonizing the legislation with international standards for medical devices and supporting in FDA accreditation

DEVELOPING RESEARCH INFRASTRUCTURE

- Providing universities and research institutions with modern research equipment
- Launching shared laboratories in cooperation with the private sector and international partners


EDUCATIONAL PROGRAMS AND TRAININGS

- Developing master's programs in tissue medicine
- Organizing internships for Ukrainian scientists and medical specialists in international research centers

EXPECTED DURATION OF THE TOP PROJECT

Long-term

7-10 YEARS




EXPECTED EFFECT

- ✓ Reduction of rehabilitation time, reduction of complications and mortality of patients with chronic and traumatic conditions
- ✓ Reduction of patients' expenses for long-term treatment and rehabilitation
- √ The development of high-tech medicine and the creation of modern research centers will help reduce labor migration among healthcare workers



DEVELOPMENT OF THE BIOCLUSTER SEGMENT IN THE WORLD

TOP-10 COUNTRIES BY LOCATION OF TOP-100 TECHNOLOGY CLUSTERS OF THE WORLD IN 2024




KEY PLAYERS IN THE CLUSTERS

- Research and development institutions
- Financial institutions (state, private investment funds)
- Technology developers
- End users of technologies

Clusters are a common tool for bringing together government, science, and business to scale up technologies, establish international relations, and promote a particular industry. Most of the world's leading clusters focus on several industries, including BioTech.

SOME BIOCLUSTERS IN THE WORLD AND THE SHARE OF REGISTERED PATENTS IN THE BIOTECH INDUSTRY IN 2024





DRIVERS OF BIOCLUSTER GROWTH IN THE WORLD



PROGRESS IN BIOTECHNOLOGY

The development of synthetic biology and the ability to program microorganisms to produce proteins, medicines, and bioplastics is increasing demand for biocluster infrastructure



The growing amount of biological data requires the creation of bioclusters that provide access to computing capacities and artificial intelligence for data analysis

FOCUS ON ENVIRONMENTAL SUSTAINABILITY



The growing use of biological materials in production, such as bioplastics and biofuels, is driving the formation of clusters aimed at creating sustainable solutions

GLOBAL GROWTH DRIVERS

ED FOR LOCALIZED PRODUCTION



Crises in global supply chains due to geopolitical events have emphasized the importance of local production of medicines and vaccines



DRIVERS AND CONSTRAINTS TO DEVELOPMENT IN UKRAINE

DRIVERS OF DEVELOPMENT IN UKRAINE





Biodiversity Ukraine creates opportunities for the development of BioTech solutions within the biocluster

CONSTRAINTS TO DEVELOPMENT IN UKRAINE

LOW LEVEL OF COOPERATION

Insufficient coordination and interaction between the government, scientific institutions, startups and businesses may hinder the creation of an effective biocluster ecosystem and further commercialization of biotechnology developments

INSUFFICIENT LEVEL OF INNOVATION CULTURE

Low level of interest in innovative products and insufficient awareness of the benefits of biotechnology in the business environment and society may hinder the effective operation and development of the biocluster and limit the domestic market for BioTech solutions

INCOMPLETE REGULATORY AND LEGAL BASIS

Complicated certification and licensing procedures and an imperfect IP protection system slow down the development and introduction of new biotechnologies to the market, while the lack of full harmonization of the regulatory framework with EU requirements limits exports

INSUFFICIENT NUMBER OF VENTURE CAPITAL FUNDS

Most BioTech startups do not have access to the necessary resources to fund research, clinical trials or scale up production. In the absence of venture capital funding, companies rely on their own funds or grant funding, which is not always stable or sufficient



ASSESSMENT OF THE FEASIBILITY OF IMPLEMENTING THE TOP PROJECT IN UKRAINE

X REQUIRED MEASURES

CREATING A VIRTUAL PLATFORM FOR COLLABORATION

- Developing an interactive portal
- Ensuring communication and crosssegment cooperation between representatives of business, startups, science and the state

CONDUCTING CONFERENCES, SEMINARS, WORKSHOPS AND OTHER EVENTS

- Providing legal advice and marketing services to promote effectively innovations in the market
- Conducting events to find investors and attract funding for technology startups based on the biocluster

ENGAGING LEADING EXPERTS IN THE BIOCLUSTER ECOSYSTEM

- Providing expert advice on product improvement and compliance with global requirements
- Assisting in finding international partners and financing opportunities for Ukrainian technology companies

X EXPECTED DURATION OF THE TOP PROJECT

Medium-term

3-5 YEARS



X EXPECTED EFFECT

- ✓ A stimulating environment has been created for the exchange of ideas, resources and expertise, as well as attracting investments for the development of BioTech solutions
- Strengthening cooperation between business, science and government to increase the number of innovative solutions and their commercialization
- Enhancing presence of Ukrainian companies and products on the global market, which will help strengthen Ukraine's innovation potential